AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacapone
Description: 200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Study NCT01497626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and bortezomib
Description: Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts.
Study NCT01090999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: long-term maintenance respiratory rehabilitation program
Description: To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
Study NCT04441099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBE-002
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor
Study NCT01568073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor
Study NCT02253602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: maximum rate of administration 1 ml/sec
Study NCT01477879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Versabase gel with sarracenia purpurea 20% liquid extract
Description: Topical application of gel/plant mix to lesions
Study NCT04529226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week
Study NCT04529226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol, pimozide, olanzapine, risperidone, amisulpride
Description: Treatment as usual using first-generation or second-generation antipsychotics
Study NCT01834781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic fields
Study NCT01834781 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: w/o pulsed electromagnetic fields
Study NCT01283815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
Study NCT01283815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management with percutaneous drainage
Description: Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
Study NCT03966391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted knowledge translation intervention
Description: The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
Study NCT01477879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (versabase gel only)
Description: versabase gel only
Study NCT00707135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
Study NCT00630786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion
Study NCT00630786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: Administered by intravenous infusion
Study NCT00386516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CT-01
Description: GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
Study NCT00386516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
Study NCT03038217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine +/- Oxaliplatin
Description: Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
Study NCT03038217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local resection
Description: Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
Study NCT03038217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical resection
Description: Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
Study NCT03038217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No adjuvant chemotherapy
Description: Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
Study NCT00971906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
Study NCT04564196 — intervention group
Intervention type: PROCEDURE
Intervention: Breath Sample
Description: breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
Study NCT02997280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet
Description: Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight > 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications.
Study NCT03316521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMY-101
Description: AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
Study NCT02261467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
Study NCT02261467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Study NCT01658579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)
Study NCT01658579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)
Study NCT01908959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Madres para la Salud
Description: Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
Study NCT01410266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative follow-up
Description: Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
Study NCT03702530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3x 50 L3 larvae immunisation with albendazole treatment
Description: Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
Study NCT03702530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3x placebo immunisation with albendazole treatment
Description: Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
Study NCT03702530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2x 50 L3 larvae infection
Description: After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
Study NCT03833154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.
Study NCT03833154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.
Study NCT03833154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Osimertinib cohort, single-arm, open-label separate cohort)
Description: Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
Study NCT02414204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
Study NCT02414204 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be over encapsulated to identical to drug comparison
Study NCT03302819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MARIA scan
Description: The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
Study NCT04100148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyncAV programmed ON
Description: For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
Study NCT04100148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed AV delay
Description: For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
Study NCT01716858 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane-rich Broccoli Sprout Extract
Study NCT01326039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: perineural bupivacaine 5 mg/ml 20 ml
Study NCT01326039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: perineural isotonic saline 20 ml
Study NCT01703923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01
Study NCT01703923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00172185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.05 mg/kg/d
Description: 0.05 mg/kg/d subcutaneous injection
Study NCT00172185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.10 mg/kg/d
Description: 0.10 mg/kg/d subcutaneous injection
Study NCT05892055 — intervention group
Intervention type: OTHER
Intervention: Procedure
Description: All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
Study NCT02749968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
Study NCT02749968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
Study NCT00982098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises
Description: After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
Study NCT02496975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
Study NCT02496975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
Study NCT03923946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion focused therapy
Description: Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
Study NCT02675088 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: high-dose TRT
Description: every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
Study NCT02675088 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard-dose TRT
Description: every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
Study NCT01824030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guided PCI
Description: FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
Study NCT01824030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided PCI
Description: OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
Study NCT03196167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
Study NCT03196167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
Study NCT03837028 — intervention group
Intervention type: OTHER
Intervention: FSFI
Description: Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
Study NCT01203007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tailored diet
Description: Tailored diet according to demonstrated food sensitivity, 6 months
Study NCT01203007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low antigen content diet
Description: Low-antigen content diet for one month
Study NCT03302767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological and Social Consultation
Description: Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
Study NCT04778124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemorrhoidal Arterial Ligation (HAL) and Recto Anal Repair (RAR)
Description: All patients underwent hemorrhoidal artery ligation on multiple sites according to pulsations detected by the doppler transducer and mucopexy (RAR) at the sites of prolapse.
Study NCT04778124 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excision of thrombosed hemorrhoid / Hemorrhoidectomy /
Description: One patient with mucosal necrosis of the hemorrhoidal cushion postoperatively underwent hemorrhoidectomy with excision of necrotic tissues.Furthermore, 2 patients who presented with hemorrhoidal thrombosis postoperatively underwent emergency surgery with supplementary excision of the thrombosed hemorrhoid. In addition, 9 patients who experienced recurrence of hemorrhoidal disease after undergoing HAL-RAR surgery, were treated with hemorrhoidectomy according to the Milligan-Morgan procedure.
Study NCT03044236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
Study NCT03044236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
Study NCT00750022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized IC treatment
Description: Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
Study NCT03766984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 25 mg
Description: Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
Study NCT03766984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg
Description: Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
Study NCT03766984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg
Description: Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)